Sleuth vs. Cortellis

Stop exporting Cortellis and checking by hand

Teams export Cortellis records, then check them by hand against company pipelines and press releases. Sleuth checks each program’s status and phase at its source, and builds the analysis your question needs.

Sleuth gives you the database for free, with analytical capabilities on top

Every Sleuth plan comes with the drugs, trials, companies, and deals you’d look up in Cortellis. Sleuth then builds the analysis for your question.

Choose Sleuth for

Landscapes, partner and asset searches, and deal comps, built on records checked at the source.

Keep Cortellis if

Your regulatory, CMC, or drug-safety team works in its regulatory products every day.

Start at $249 a month instead of $20K+ a year

A database subscription

$20K+ a year

The database alone. The analysis is still on you.

Sleuth

From $249 a month

Everything your database has, plus 3,000 credits a month.

See every plan

How Sleuth and Cortellis compare

Sleuth

Cortellis

The database

Sleuth

Included in every plan: drugs, trials, companies, and deals in one knowledge base. Browsing is free and doesn’t use credits.

Cortellis

Sold product by product: pipeline, deals, trials, and regulatory data are each a separate product.

Your columns

Sleuth

The standard fields, plus any column you ask for. Ask “who holds the rights outside the US?” and Sleuth adds it as a column, filled in for every program.

Cortellis

Limited to its “more than 20 granular filters.” For anything else, you export the records and work it out by hand.

Sources

Sleuth

Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.

Cortellis

You check the records yourself, against company pipelines and press releases. Its AI assistant answers from the same records.

Program status

Sleuth

Tens of thousands of updates a day, each checked at its source: company pipelines, filings, 20 trial registries, and news. A stopped program shows as stopped, with the reason when there’s a public one.

Cortellis

Buyers tell us a program can stay listed as active after the company drops it, and the reason it stopped is rarely recorded.

Phase

Sleuth

Taken from each program’s own registry entry or filing, with the source beside it.

Cortellis

An early program can stay listed as preclinical after it has started Phase 2.

China

Sleuth

About 22,000 Chinese programs, read in Chinese from China’s registries, filings, and patents.

Cortellis

Chinese programs often show up late, once an English source reports them.

Keeping it current

Sleuth

Turn on monitoring, and the dataset updates as trials, filings, and deals come in, with a change log and earlier versions kept.

Cortellis

Alerts on the records you follow, but a landscape you exported doesn’t update. You rebuild it.

AI

Sleuth

Builds the analysis for your question from the knowledge base and the documents behind it, in Studio or in Claude, ChatGPT, and Copilot.

Cortellis

Its AI assistant answers from the same fixed fields as the database.

Sell-side research

Sleuth

From 35+ providers, in every plan. Read any report in full, and search it next to the knowledge base.

Cortellis

Not part of Cortellis.

Every program checked at its source

Cortellis users tell us its records lag: stopped programs still listed as active, Phase 2 programs still called preclinical. Sleuth checks company pipelines, filings, 20 trial registries, and news, and makes tens of thousands of updates a day.

Example

When a program stops, Sleuth records why

Program

Company

Status

Why it stopped

ABBV-787

AbbVie

Stopped, Feb 2025

Strategic termination

ORM-5029

Orum

Stopped, Apr 2025

Safety

BMS-986497

BMS

Stopped, Sep 2026

After Phase 1 data review

ORM-1153

Orum

In Phase 1

Degrader-antibody conjugates that reached the clinic. Source: Sleuth’s Protein Degraders report, September 2026.

6 of 10

degraders stopped at targets with an approved drug had been tested in patients resistant to that drug. That pattern shows only when every stop has its reason.

See how a graveyard analysis works

Early programs, when they’re first disclosed

Cortellis sells itself on early pipeline coverage, yet it often lists Chinese and early programs late. Sleuth reads patents and China’s registries and filings, so you see a program when it’s first disclosed.

~22,000

Chinese programs, read in Chinese

~60%

of the 150K+ drugs in the knowledge base are preclinical

300K+

patents, where new programs often show up first

See China coverage

One knowledge base instead of separate products

Cortellis sells pipeline, deal, trial, and regulatory data as separate products, joined “with direct links and single sign-on.” In Sleuth, they’re one knowledge base, with sell-side research beside it.

Pipeline and competitors

A separate Cortellis product

Clinical trials

A separate Cortellis product

Deals

A separate Cortellis product

Sell-side research

Not part of Cortellis

See what’s in the knowledge base

When to keep Cortellis

Keep Cortellis if your regulatory, CMC, or drug-safety team works in its regulatory products every day. For pipeline, landscape, and BD work, Sleuth replaces it, and builds the analysis on top.

Tracks rules market by market

Your regulatory team follows guidance and submission requirements country by country.

Plans CMC filings

Your CMC team checks manufacturing regulations and local practice before each submission.

Reviews safety signals

Your safety team looks for drug and class toxicity across preclinical and clinical data.

Questions about Sleuth and Cortellis

Can Sleuth replace Cortellis?

For pipeline, landscape, and BD work, yes: competitive landscapes, asset and partner searches, and deal comps. Every plan includes the drugs, trials, companies, and deals you’d look up in Cortellis. Keep Cortellis if your regulatory, CMC, or drug-safety team works in its regulatory products every day.

How does Sleuth know a program has stopped?

It checks each program at its source: company pipeline pages and filings, 20 trial registries, and news. When a program drops off a pipeline or its trial ends, Sleuth updates the status and records the reason the company gave. When there’s no stated reason, Sleuth infers one from the last reported data and marks it inferred, with the sources beside it.

What does every Sleuth plan include?

Analysis built for your question, a knowledge base of drugs, trials, companies, and deals, and searchable documents, including sell-side research from 35+ providers. Browsing the knowledge base and reading the research are free. You can try all of it free for 14 days.

Does Cortellis have AI?

Yes. In August 2026, Cortellis added agentic workflows to its competitive intelligence product. They answer from the same records as the database. Sleuth builds the analysis for your question from its knowledge base and the documents behind it, with a source on every value.

Does Sleuth cover Chinese programs?

Yes, about 22,000, read in Chinese from China’s registries, filings, patents, and medical meetings, in the same landscape as every other program.

Can I bring my Cortellis exports into Sleuth?

Yes. Upload your own files in Studio, and Sleuth reads them alongside its knowledge base and documents.

Check a landscape you know in Sleuth

Set up in Claude, ChatGPT, or Copilot